FDA orders NAION eye-risk warning across GLP-1 class, covering Lilly's Mounjaro, Zepbound and Foundayo

On November 9, 2026 the FDA issued a safety communication requiring makers of all GLP-1 receptor agonists to add a warning about non-arteritic anterior ischemic optic neuropathy, a rare eye condition that can cause permanent vision loss in one eye. The agency pooled 126 randomized trials covering about 134,000 patients and reported a rate of 6.4 NAION cases per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or non-GLP-1 glucose-lowering comparators. The label change reaches Lilly's tirzepatide franchise (Mounjaro and Zepbound) and its oral GLP-1 Foundayo (orforglipron). Novo Nordisk says the data do not establish a causal link. Lilly had not publicly responded at the time of the reporting seen here, so the company-level commercial effect remains unquantified.

1. FDA safety communication issued November 9, 2026 on a potential association between GLP-1 medications and NAION.
2. FDA is requiring makers of all GLP-1 receptor agonist drugs to add the NAION warning to labeling.
3. FDA pooled 126 randomized trials with 134,253 patients.
4. NAION rate: 6.4 cases per 100,000 person-years on GLP-1 RA users vs 3.8 on placebo or non-GLP-1 glucose-lowering drugs.
5. Affected Lilly products named in coverage: Mounjaro, Zepbound and Foundayo.
6. Novo Nordisk said available data do not establish a cause-and-effect relationship.
7. Lilly did not immediately respond to a request for comment at the time of the Benzinga report.